A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 80-mg Tablets to OxyContin 80-mg Tablets.
Phase of Trial: Phase I
Latest Information Update: 17 May 2010
At a glance
- Drugs Oxycodone (Primary)
- Indications Cancer pain; Pain
- Focus Pharmacokinetics
- Sponsors Purdue Pharma
- 12 May 2010 Primary outcome amended as reported by ClinicalTrials.gov.
- 12 Apr 2010 New trial record